NASDAQ:GTBP GT Biopharma (GTBP) Stock Price, News & Analysis $2.74 -0.02 (-0.72%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.72▼$2.8050-Day Range$2.66▼$7.8052-Week Range$2.60▼$10.66Volume2,712 shsAverage Volume621,608 shsMarket Capitalization$3.89 millionP/E RatioN/ADividend YieldN/APrice Target$150.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get GT Biopharma alerts: Email Address GT Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside5,374.5% Upside$150.00 Price TargetShort InterestHealthy0.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.45Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 stars 3.5 Analyst's Opinion Consensus RatingGT Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGT Biopharma has received no research coverage in the past 90 days.Read more about GT Biopharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.82% of the float of GT Biopharma has been sold short.Short Interest Ratio / Days to CoverGT Biopharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GT Biopharma has recently decreased by 61.63%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGT Biopharma does not currently pay a dividend.Dividend GrowthGT Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GTBP. Previous Next 3.0 News and Social Media Coverage News SentimentGT Biopharma has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for GT Biopharma this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GT Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.00% of the stock of GT Biopharma is held by insiders.Percentage Held by InstitutionsOnly 8.15% of the stock of GT Biopharma is held by institutions.Read more about GT Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioGT Biopharma has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GT Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About GT Biopharma Stock (NASDAQ:GTBP)GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Read More GTBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTBP Stock News HeadlinesJune 27, 2024 | globenewswire.comGT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ LeukemiaMay 21, 2024 | marketwatch.comGT Biopharma Shares Rise 16% After Direct Offering PricesJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 21, 2024 | markets.businessinsider.comGT Biopharma Announces $3.2 Mln Direct Offering Of Shares; Stock UpMay 21, 2024 | globenewswire.comGT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 20, 2024 | investorplace.comWhy Is GT Biopharma (GTBP) Stock Up 143% Today?May 18, 2024 | nasdaq.comGT Biopharma, Inc. Common Stock (GTBP)May 16, 2024 | benzinga.comRaymond W. Urbanski's Net WorthJuly 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.May 16, 2024 | investorplace.comGTBP Stock Earnings: GT Biopharma Beats EPS for Q1 2024May 15, 2024 | msn.comGT Biopharma reports Q1 resultsMay 15, 2024 | globenewswire.comGT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMarch 27, 2024 | benzinga.comRecap: GT Biopharma Q4 EarningsMarch 26, 2024 | globenewswire.comGT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 25, 2024 | msn.comGT Biopharma (GTBP) Price Target Increased by 2900.00% to 153.00February 14, 2024 | finance.yahoo.comGTBP Feb 2024 2.500 callFebruary 2, 2024 | finance.yahoo.comGT Biopharma, Inc. (GTBP)February 2, 2024 | msn.comGT Biopharma Announces Reverse Stock Split UpdateSee More Headlines Receive GTBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GTBP Previous SymbolOTCMKTS:OXISD CUSIPN/A CIK109657 Webwww.gtbiopharma.com Phone(415) 919-4040FaxN/AEmployees8Year Founded1965Price Target and Rating Average Stock Price Target$150.00 High Stock Price Target$150.00 Low Stock Price Target$150.00 Potential Upside/Downside+5,374.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-135.49% Return on Assets-80.28% Debt Debt-to-Equity RatioN/A Current Ratio2.15 Quick Ratio2.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.42 per share Price / Book0.51Miscellaneous Outstanding Shares1,420,000Free Float1,275,000Market Cap$3.89 million OptionableNo Data Beta0.65 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Michael Martin Breen (Age 61)Interim CEO & Executive Chairman Comp: $1.04MMr. Manu Ohri (Age 69)CFO & Secretary Comp: $647.07kDr. Jeffrey S. Miller M.D.Consulting Chief Scientific Officer, Consulting Chief Medical Officer & Scientific AdvisorKey CompetitorsSonoma PharmaceuticalsNASDAQ:SNOAJaguar HealthNASDAQ:JAGXUnicycive TherapeuticsNASDAQ:UNCYKiora PharmaceuticalsNASDAQ:KPRXGuardion Health SciencesNASDAQ:GHSIView All CompetitorsInstitutional OwnershipDekaBank Deutsche GirozentraleBought 1,093,645 shares on 6/4/2024Ownership: 77.017%View All Institutional Transactions GTBP Stock Analysis - Frequently Asked Questions How have GTBP shares performed this year? GT Biopharma's stock was trading at $7.65 on January 1st, 2024. Since then, GTBP shares have decreased by 64.2% and is now trading at $2.74. View the best growth stocks for 2024 here. How were GT Biopharma's earnings last quarter? GT Biopharma, Inc. (NASDAQ:GTBP) issued its quarterly earnings data on Wednesday, May, 15th. The company reported ($2.12) earnings per share for the quarter, beating analysts' consensus estimates of ($2.70) by $0.58. When did GT Biopharma's stock split? Shares of GT Biopharma reverse split on Monday, February 5th 2024. The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of GT Biopharma? Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GTBP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
